Zeidan, A. M., Wang, E. S., Issa, G. C., Erba, H., Altman, J. K., Balasubramanian, S. K., … Fathi, A. T. (2024). Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. In Blood (Vol. 144, pp. 214–214). American Society of Hematology. https://doi.org/10.1182/blood-2024-198218

Zeidan, Amer M., Eunice S. Wang, Ghayas C. Issa, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Stephen Anthony Strickland, et al. “Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007.” In Blood, 144:214–214. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-198218.

Zeidan AM, Wang ES, Issa GC, Erba H, Altman JK, Balasubramanian SK, et al. Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. In: Blood. American Society of Hematology; 2024. p. 214–214.

Zeidan, Amer M., et al. “Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 214–214. Crossref, doi:10.1182/blood-2024-198218.

Zeidan AM, Wang ES, Issa GC, Erba H, Altman JK, Balasubramanian SK, Strickland SA, Roboz GJ, Schiller GJ, McMahon CM, Palmisiano ND, Madanat YF, Rotta M, Nadiminti K, Wei H, Riches M, Corum D, Leoni M, Dale S, Fathi AT. Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood. American Society of Hematology; 2024. p. 214–214.